As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Guest edited by Associate Editor, Professor Robert Bals (Saarland University, Germany), this series of articles provides newest research and comprehensive background information on e-cigarettes. The articles aim to address the needs of basic researchers, clinicians and other individuals that need up-to-data information on this topic.
Respiratory Research is pleased to still be accepting submissions for this thematic series.
The vaping craze has swept the nation, advertised as a ‘better’ alternative to smoking. But is this really true? In a recent article published in Respiratory Research, Deirdre Gilpin and her colleagues explored whether exposure to electronic cigarette vapour (ECV), compared to cigarette smoke extract (CSE) resulted in changes in specific lung bacteria’s potential to cause harm.
Featured article: Genetic influences on the onset of obstructive sleep apnoea and daytime sleepiness: a twin study
Obstructive sleep apnoea (OSA) is one of the major sources of the excessive daily sleepiness, cognitive dysfunction, and it increases cardiovascular morbidity and mortality. Previous studies suggested a possible genetic influence but no objective genetic study was conducted to understand the exact variance underpinned by genetic factors. In this study, seventy-one Hungarian twin pairs involved from the Hungarian Twin Registry underwent overnight polysomnography. Findings demonstrated that obstructive sleep apnoea and the indices of OSA severity are heritable while daytime sleepiness is mostly influenced by environmental factors.
About the Editors
Dr. Kelan Tantisira, of the Brigham and Women’s Hospital and Harvard Medical School, has directed seminal studies in respiratory epidemiology, genomics, and pharmacogenomics, as well as in the fetal genomic orgins of lung disease. His work focuses primarily on factors influencing asthma susceptibility, severity, prognosis, and treatment response, with particular interests in asthma pharmacogenomics, translational genomics, and personalized, prognostic medicine.
Prof. Bals is the director of the Saarland University’s Department of Pulmonology, where Prof. Bals focuses on teaching, research, and patient care. In the research area, Prof. Bals covers preclinical and clinical research and has contributed to 250 papers and several books. His research areas are inflammatory lung disease, asthma, COPD, and infection. In the basic science laboratory, Prof. Bals and his team investigate the mechanisms how the lung interacts with the environment including smoke, allergens, and microorganisms with a focus on stem cell biology and regeneration. In clinical research, he performs investigations in COPD, asthma, pneumonia and cystic fibrosis. He established and manages the German alpha-1-antitrypsin registry and is member of the steering committee of COSYCONET.
Submit your review
Click here to view the most shared articles in the last month!
Aims and scope
Respiratory Research publishes high-quality clinical and basic research, review and commentary articles on all aspects of respiratory medicine and related diseases.
As the leading fully open access journal in the field, Respiratory Research provides an essential resource for pulmonologists, allergists, immunologists and other physicians, researchers, healthcare workers and medical students with worldwide dissemination of articles resulting in high visibility and generating international discussion.
Robert Bals, Saarland University, Germany
Kelan Tantisira, Brigham and Women's Hospital, USA
Takuya Aoki, Tokai University School of Medicine, Japan
Francesco Blasi, University of Milan, Italy
Su Bo, Shanghai Pulmonary Hospital, China
Arnaud Bourdin, University of Montpellier, France
Mario Cazzola, University of Rome Tor Vergata, Italy
Sanjay Haresh Chotirmall, Lee Kong Chian School of Medicine, Singapore
Suzanne Cloonan, Weill Cornell Medicine, USA
Taylor Cohen, MedImmune, USA
Bruno Crestani, Bichat Hospital, France
Jeanine D'Armiento, Columbia University College of Physicians and Surgeons, USA
Olivier Danhaive, University of California San Francisco, USA
Massimo Di Maio, University of Turin, Italy
Louise Donnelly, Imperial College London, UK
Eric Garshick, VA Boston Healthcare System, USA
Kathleen Haley, Brigham and Women's Hospital, USA
Michael Kreuter, Universitatsklinikum Heidelberg, Germany
Guha Krishnaswamy, Wake Baptist Hospital, USA
Larry Lands, McGill University, Canada
Victor Laubach, University of Virginia, USA
Yasuhiko Nishioka, Tokushima University, Japan
Stylianos Orfanos, National and Kapodistrian University of Athens, Greece
Victor Ortega, Wake Forest School of Medicine, USA
Reynold A. Panettieri Jr, Rutgers, The State University of New Jersey, USA
Massimo Pistolesi, University of Florence, Italy
YS Prakash, Mayo Clinic, USA
Jennifer Quint, Imperial College London, UK
Sunit Singh, Banaras Hindu University, India
Giovanni Sotgiu, University of Sassari, Italy
Dale D Tang, Albany Medical College, USA
Johan Verbraecken, Antwerp University Hospital, Belgium
Marlies Wijsenbeek, Erasmus University Rotterdam, Netherlands
Annual Journal Metrics
61 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
126 days from submission to acceptance
18 days from acceptance to publication
2,375 Altmetric mentions